Table 3. Open in new tab MIC and...

Years/antimicrobial agent	N					Susceptibility
2009–11
AMC^a,b	434	1	4	≤0.015	128	89.2	6.0	4.8	89.2 (95.2)	NA	NA	NA
cefaclor	434	16	>256	0.12	>256	40.3	2.1	57.6	35.3	0.0	35.3	64.7
cefuroxime^c	434	2	16	≤0.015	>256	44.2	9.9	45.9	44.2	41.2	3.7	58.8
levofloxacin	434	1	1	0.12	>32	97.5	0.2	2.3	97.5	97.5	—	2.5
penicillin (oral)	434	1	2	≤0.015	32	36.2	35.5	28.3	NA	36.2	53.9	9.9
penicillin (iv)	434	1	2	≤0.015	32	90.1	6.5	3.4	NA	49.1–90.1	NA	NA
chloramphenicol^d	434	NA	NA	NA	NA	85.9	0.0	14.1	NA	85.9	0.0	14.1
clindamycin^d	434	NA	NA	NA	NA	9.2	0.5	90.3	NA	9.2	0.0	90.8
erythromycin^d	434	NA	NA	NA	NA	7.8	0.7	91.5	NA	7.8	0.2	91.9
tetracycline^d	434	NA	NA	NA	NA	6.0	3.2	90.8	NA	9.2	4.2	86.6
SXT^d	434	NA	NA	NA	NA	24.2	5.3	70.5	NA	27.0	3.0	70.1
2013–14
AMC^a,b	208	1	8	≤0.015	64	75.0	13.5	11.5	75.0 (88.5)	NA	NA	NA
cefaclor	208	>256	>256	0.25	>256	22.6	13.0	64.4	7.7	0.0	7.7	92.3
cefuroxime^c	208	2	32	≤0.015	>256	43.3	10.5	46.2	43.3	36.5	4.8	58.7
levofloxacin	208	1	2	0.25	>32	99.0	0.0	1.0	99.0	99.0	—	1.0
penicillin (oral)	208	1	4	≤0.015	32	32.2	33.2	34.6	NA	32.2	51.5	16.3
penicillin (iv)	208	1	4	≤0.015	32	83.7	13.4	2.9	NA	49.5–83.7	NA	NA
chloramphenicol^d	208	NA	NA	NA	NA	90.9	0.0	9.1	NA	90.9	0.0	9.1
clindamycin^d	208	NA	NA	NA	NA	6.2	0.5	93.3	NA	6.2	0.0	93.8
erythromycin^d	208	NA	NA	NA	NA	4.3	1.9	93.8	NA	4.3	1.0	94.7
tetracycline^d	208	NA	NA	NA	NA	0.0	0.0	100	NA	0.0	6.2	93.8
SXT^d	208	NA	NA	NA	NA	26.4	4.3	69.2	NA	28.4	2.4	69.2

Years/antimicrobial agent

Susceptibility

MIC (mg/L)

CLSI

PK/PD

EUCAST

50%

90%

min.

max.

2009–11

AMC^a,b

434

≤0.015

128

89.2

6.0

4.8

89.2 (95.2)

cefaclor

434

>256

0.12

>256

40.3

2.1

57.6

35.3

0.0

35.3

64.7

cefuroxime^c

434

≤0.015

>256

44.2

9.9

45.9

44.2

41.2

3.7

58.8

levofloxacin

434

0.12

>32

97.5

0.2

2.3

97.5

—

2.5

penicillin (oral)

434

≤0.015

36.2

35.5

28.3

36.2

53.9

9.9

penicillin (iv)

434

≤0.015

90.1

6.5

3.4

49.1–90.1

chloramphenicol^d

434

85.9

0.0

14.1

85.9

0.0

14.1

clindamycin^d

434

9.2

0.5

90.3

9.2

0.0

90.8

erythromycin^d

434

7.8

0.7

91.5

7.8

0.2

91.9

tetracycline^d

434

6.0

3.2

90.8

9.2

4.2

86.6

SXT^d

434

24.2

5.3

70.5

27.0

3.0

70.1

2013–14

AMC^a,b

208

≤0.015

75.0

13.5

11.5

75.0 (88.5)

cefaclor

208

>256

0.25

>256

22.6

13.0

64.4

7.7

0.0

7.7

92.3

cefuroxime^c

208

≤0.015

>256

43.3

10.5

46.2

43.3

36.5

4.8

58.7

levofloxacin

208

0.25

>32

99.0

0.0

1.0

99.0

—

1.0

penicillin (oral)

208

≤0.015

32.2

33.2

34.6

32.2

51.5

16.3

penicillin (iv)

208

≤0.015

83.7

13.4

2.9

49.5–83.7

chloramphenicol^d

208

90.9

0.0

9.1

90.9

0.0

9.1

clindamycin^d

208

6.2

0.5

93.3

6.2

0.0

93.8

erythromycin^d

208

4.3

1.9

93.8

4.3

1.0

94.7

tetracycline^d

208

0.0

100

0.0

6.2

93.8

SXT^d

208

26.4

4.3

69.2

28.4

2.4

69.2

Years/antimicrobial agent	N					Susceptibility
2009–11
AMC^a,b	434	1	4	≤0.015	128	89.2	6.0	4.8	89.2 (95.2)	NA	NA	NA
cefaclor	434	16	>256	0.12	>256	40.3	2.1	57.6	35.3	0.0	35.3	64.7
cefuroxime^c	434	2	16	≤0.015	>256	44.2	9.9	45.9	44.2	41.2	3.7	58.8
levofloxacin	434	1	1	0.12	>32	97.5	0.2	2.3	97.5	97.5	—	2.5
penicillin (oral)	434	1	2	≤0.015	32	36.2	35.5	28.3	NA	36.2	53.9	9.9
penicillin (iv)	434	1	2	≤0.015	32	90.1	6.5	3.4	NA	49.1–90.1	NA	NA
chloramphenicol^d	434	NA	NA	NA	NA	85.9	0.0	14.1	NA	85.9	0.0	14.1
clindamycin^d	434	NA	NA	NA	NA	9.2	0.5	90.3	NA	9.2	0.0	90.8
erythromycin^d	434	NA	NA	NA	NA	7.8	0.7	91.5	NA	7.8	0.2	91.9
tetracycline^d	434	NA	NA	NA	NA	6.0	3.2	90.8	NA	9.2	4.2	86.6
SXT^d	434	NA	NA	NA	NA	24.2	5.3	70.5	NA	27.0	3.0	70.1
2013–14
AMC^a,b	208	1	8	≤0.015	64	75.0	13.5	11.5	75.0 (88.5)	NA	NA	NA
cefaclor	208	>256	>256	0.25	>256	22.6	13.0	64.4	7.7	0.0	7.7	92.3
cefuroxime^c	208	2	32	≤0.015	>256	43.3	10.5	46.2	43.3	36.5	4.8	58.7
levofloxacin	208	1	2	0.25	>32	99.0	0.0	1.0	99.0	99.0	—	1.0
penicillin (oral)	208	1	4	≤0.015	32	32.2	33.2	34.6	NA	32.2	51.5	16.3
penicillin (iv)	208	1	4	≤0.015	32	83.7	13.4	2.9	NA	49.5–83.7	NA	NA
chloramphenicol^d	208	NA	NA	NA	NA	90.9	0.0	9.1	NA	90.9	0.0	9.1
clindamycin^d	208	NA	NA	NA	NA	6.2	0.5	93.3	NA	6.2	0.0	93.8
erythromycin^d	208	NA	NA	NA	NA	4.3	1.9	93.8	NA	4.3	1.0	94.7
tetracycline^d	208	NA	NA	NA	NA	0.0	0.0	100	NA	0.0	6.2	93.8
SXT^d	208	NA	NA	NA	NA	26.4	4.3	69.2	NA	28.4	2.4	69.2

Table 3.

Open in new tab

MIC and susceptibility data for S. pneumoniae isolates collected during 2009–11 and 2013–14

Years/antimicrobial agent	N					Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
		50%	90%	min.	max.	%S	%I	%R	%S	%S	%I	%R
2009–11
AMC^a,b	434	1	4	≤0.015	128	89.2	6.0	4.8	89.2 (95.2)	NA	NA	NA
cefaclor	434	16	>256	0.12	>256	40.3	2.1	57.6	35.3	0.0	35.3	64.7
cefuroxime^c	434	2	16	≤0.015	>256	44.2	9.9	45.9	44.2	41.2	3.7	58.8
levofloxacin	434	1	1	0.12	>32	97.5	0.2	2.3	97.5	97.5	—	2.5
penicillin (oral)	434	1	2	≤0.015	32	36.2	35.5	28.3	NA	36.2	53.9	9.9
penicillin (iv)	434	1	2	≤0.015	32	90.1	6.5	3.4	NA	49.1–90.1	NA	NA
chloramphenicol^d	434	NA	NA	NA	NA	85.9	0.0	14.1	NA	85.9	0.0	14.1
clindamycin^d	434	NA	NA	NA	NA	9.2	0.5	90.3	NA	9.2	0.0	90.8
erythromycin^d	434	NA	NA	NA	NA	7.8	0.7	91.5	NA	7.8	0.2	91.9
tetracycline^d	434	NA	NA	NA	NA	6.0	3.2	90.8	NA	9.2	4.2	86.6
SXT^d	434	NA	NA	NA	NA	24.2	5.3	70.5	NA	27.0	3.0	70.1
2013–14
AMC^a,b	208	1	8	≤0.015	64	75.0	13.5	11.5	75.0 (88.5)	NA	NA	NA
cefaclor	208	>256	>256	0.25	>256	22.6	13.0	64.4	7.7	0.0	7.7	92.3
cefuroxime^c	208	2	32	≤0.015	>256	43.3	10.5	46.2	43.3	36.5	4.8	58.7
levofloxacin	208	1	2	0.25	>32	99.0	0.0	1.0	99.0	99.0	—	1.0
penicillin (oral)	208	1	4	≤0.015	32	32.2	33.2	34.6	NA	32.2	51.5	16.3
penicillin (iv)	208	1	4	≤0.015	32	83.7	13.4	2.9	NA	49.5–83.7	NA	NA
chloramphenicol^d	208	NA	NA	NA	NA	90.9	0.0	9.1	NA	90.9	0.0	9.1
clindamycin^d	208	NA	NA	NA	NA	6.2	0.5	93.3	NA	6.2	0.0	93.8
erythromycin^d	208	NA	NA	NA	NA	4.3	1.9	93.8	NA	4.3	1.0	94.7
tetracycline^d	208	NA	NA	NA	NA	0.0	0.0	100	NA	0.0	6.2	93.8
SXT^d	208	NA	NA	NA	NA	26.4	4.3	69.2	NA	28.4	2.4	69.2

Years/antimicrobial agent	N					Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
		50%	90%	min.	max.	%S	%I	%R	%S	%S	%I	%R
2009–11
AMC^a,b	434	1	4	≤0.015	128	89.2	6.0	4.8	89.2 (95.2)	NA	NA	NA
cefaclor	434	16	>256	0.12	>256	40.3	2.1	57.6	35.3	0.0	35.3	64.7
cefuroxime^c	434	2	16	≤0.015	>256	44.2	9.9	45.9	44.2	41.2	3.7	58.8
levofloxacin	434	1	1	0.12	>32	97.5	0.2	2.3	97.5	97.5	—	2.5
penicillin (oral)	434	1	2	≤0.015	32	36.2	35.5	28.3	NA	36.2	53.9	9.9
penicillin (iv)	434	1	2	≤0.015	32	90.1	6.5	3.4	NA	49.1–90.1	NA	NA
chloramphenicol^d	434	NA	NA	NA	NA	85.9	0.0	14.1	NA	85.9	0.0	14.1
clindamycin^d	434	NA	NA	NA	NA	9.2	0.5	90.3	NA	9.2	0.0	90.8
erythromycin^d	434	NA	NA	NA	NA	7.8	0.7	91.5	NA	7.8	0.2	91.9
tetracycline^d	434	NA	NA	NA	NA	6.0	3.2	90.8	NA	9.2	4.2	86.6
SXT^d	434	NA	NA	NA	NA	24.2	5.3	70.5	NA	27.0	3.0	70.1
2013–14
AMC^a,b	208	1	8	≤0.015	64	75.0	13.5	11.5	75.0 (88.5)	NA	NA	NA
cefaclor	208	>256	>256	0.25	>256	22.6	13.0	64.4	7.7	0.0	7.7	92.3
cefuroxime^c	208	2	32	≤0.015	>256	43.3	10.5	46.2	43.3	36.5	4.8	58.7
levofloxacin	208	1	2	0.25	>32	99.0	0.0	1.0	99.0	99.0	—	1.0
penicillin (oral)	208	1	4	≤0.015	32	32.2	33.2	34.6	NA	32.2	51.5	16.3
penicillin (iv)	208	1	4	≤0.015	32	83.7	13.4	2.9	NA	49.5–83.7	NA	NA
chloramphenicol^d	208	NA	NA	NA	NA	90.9	0.0	9.1	NA	90.9	0.0	9.1
clindamycin^d	208	NA	NA	NA	NA	6.2	0.5	93.3	NA	6.2	0.0	93.8
erythromycin^d	208	NA	NA	NA	NA	4.3	1.9	93.8	NA	4.3	1.0	94.7
tetracycline^d	208	NA	NA	NA	NA	0.0	0.0	100	NA	0.0	6.2	93.8
SXT^d	208	NA	NA	NA	NA	26.4	4.3	69.2	NA	28.4	2.4	69.2

AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available; SXT, trimethoprim/sulfamethoxazole.

^aAMC, amoxicillin/clavulanic acid PK/PD susceptibility at high dose is shown in parentheses.

^bSusceptibility for amoxicillin alone can be inferred from amoxicillin/clavulanic acid.

^cBreakpoints used are for cefuroxime axetil.

^dCLSI disc diffusion testing method used.

This Feature Is Available To Subscribers Only